   
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Research Excellence Awards Chair - Application of Pharmacoeconomics
and Health Outcomes Research Description: ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Excellence was established in 1997 to recognize outstanding practical application of pharmacoeconomics and outcomes research in health care decision-making. Criteria: The award is given to a distinguished example of applied health outcomes research that has or is expected to have a high impact on health policy or healthcare decision making. Preference is given to papers with creative application of health outcomes research, encompassing topics such as health policy, evaluation and adoption of health technologies, and other issues that further the goals and objectives of the Society. The award is selected by the ISPOR Excellence Awards Committee from nominated papers that have appeared in print or e-pub in peer-review journals during the preceding calendar year (e-pub must be listed in Medline) and other communication venues (e.g. books, reports). Self-nominations are encouraged and accepted for consideration. Selection Process: A call for nominations is placed in November-December ISPOR CONNECTIONS for articles published during the past twelve months to be considered for the ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research. In addition, each Excellence Award Committee member selects relevant publications in respected peer-reviewed journals during the preceding twelve months to be considered by the Awards Committee in the selection process. The Excellence Award Committee meets via teleconference in February to discuss each of the nominated publications. They select the best demonstration of scientific excellence for that time period. The nominee is then forwarded to the Board of Directors for final approval. The corresponding author on the publication is given the award. Nature of Award: The Award, presented at the ISPOR Annual International Meeting to the corresponding author of the paper, consists of a plaque, complimentary Annual International Meeting registration, roundtrip air fare, hotel, meal and miscellaneous expenses for two days, based upon current ISPOR travel policies. Nominations for the ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research should be accompanied by an electronic version of the nominated paper and a letter of support that illustrates the positive attributes of the paper, and sent to awards@ispor.org. Only ISPOR members may submit nominations (either their own publications or others). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Niteesh K. Choudhry, MD, PhD, Associate Professor, Harvard Medical School, Boston, MA, USA For the paper, “Full Coverage for Preventive Medications after Myocardial Infarction” N Engl J Med 2011;365:2088-97. Niteesh K. Choudhry, MD, PhD, is an internist and health services researcher whose work focuses on the clinical and economic consequences of evidence-based therapies for the management of common chronic conditions. He is particularly interested in the design and evaluation of novel strategies to overcome barriers to treatment initiation and long-term medication adherence. His work employs a broad range of methods including randomized policy evaluations, cost-effectiveness modeling, claims analyses, and surveys. Dr. Choudhry is an Associate Professor at Harvard Medical School and Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. He received his MD and completed his residency training in Internal Medicine at the University of Toronto, did his PhD in Health Policy at Harvard University and was a Fellow in Pharmaceutical Policy Research at Harvard Medical School. He practices inpatient general internal/hospital medicine and is actively involved in resident education. 
Craig J. Currie, PhD Having followed an unconventional career path spanning some 25 years, Craig Currie has held appointments at five universities: Leicester, York, Dundee, Queensland and primarily in the School of Medicine at Cardiff University. Craig has also worked in industry in health outcomes, but for the last 11 years he has established and headed 2 research service companies. His current part-time, academic appointment is Reader in Diabetes Pharmacoepidemiology. The remainder of his time is spent servicing industry through his company, Pharmatelligence who carry out complex pharmacoeconomics and pharmacoepidemiology studies, and develop & manage disease registers. Craig and his team are particularly experienced in the use of routine health care data for the provision of health intelligence. Research into the economics and epidemiology of diabetes has been a long established hobby which has allowed for development of the necessary familiarity and confidence to now challenge some of the most vehemently held tenets in diabetes. The study related to this award represents a good example of this. 
Ties Hoomans PhD, MSc Value of Information And Value Of Implementation: Application Of An Analytic Framework To Inform Resource Allocation Decisions In Metastatic Hormone-Refractory Prostate Cancer. Value Health 2009;12:315-24. Ties Hoomans (PhD in Health Economics; MSc in Industrial Engineering and Management) is a Post Doctoral Research Fellow based in the Health Technology Assessment research program at the School for Public Health and Primary Care, Maastricht University, The Netherlands. He is also an associate member of the Health Economic Appraisals team at the University of Glasgow, United Kingdom. Hoomans was previously appointed as an advisor at the Dutch Health Care Insurance Board, and he conducted his PhD research on ‘Economic evaluation of change in clinical practice’ from 2004 till 2008. Hoomans’ research centres on the economic evaluation of health care technologies, with specific interest in implementation research and decision analysis. He has presented innovative methods for assessing the value of actively implementing evidence based care. Currently, his work concentrates on demonstrating the practicality of the methodology, while incorporating value of information methods. His research includes establishing more pragmatic applications of economic evaluations (e.g. risk sharing or coverage with evidence development schemes) and exploring the (potential) role of health economic information in decision making processes.  Maureen Rutten van Mölken PhD Associate Professor Health Economics Institute for Medical Technology Assessment Erasmus University/Erasmus Medical Centre, Rotterdam, The Netherlands Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPM. Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. Value in Health 2008;11:1070-80. Maureen Rutten-van Mölken is an Associate Professor in Health Economics at the Institute for Medical Technology Assessment/Institute of Health Care Policy and Management (IMTA/IBMG) of the Erasmus University/Erasmus Medical Centre in Rotterdam. She is vice-director of IMTA. She joint IMTA as a senior researcher in 1996. Before, she was an assistant professor in Health Economics and Medical Technology Assessment at the Department of Health Economics of the University of Maastricht. She was trained as a health scientist and had additional training in health economics and epidemiology. She obtained an MSc in health care policy and management at Maastricht University (1988), and a PhD in health economics, also at Maastricht University (1994). Her expertise includes economic evaluations alongside clinical trials as well as probabilistic decision analytic modeling of the cost-effectiveness of health care interventions, primarily in the area of respiratory diseases, smoking, rheumatology and several other chronic diseases. She has 20 years of experience in health economics and outcomes research and has been project leader of many applied economic evaluations and HTA-methodology studies leading to high level publications. She is a member of the committee “Implementation” of the Netherlands Organization for Health Research and Development (ZonMW), and a member of the scientific advisory board of the Dutch Asthma Foundation.  Greg Zaric PhD Zaric G, Brandeau ML. A little planning goes a long way: multilevel allocation of hiv prevention resources. Med Decis Making 2007;27:71-81. Greg Zaric is an Associate Professor in the Management Science group at the Richard Ivey School of Business, as well as an Associate Professor of Epidemiology and Biostatistics at the Schulich School of Medicine and Dentistry, University of Western Ontario. His research focuses on applications of operations research and management science to problems in pharmacoeconomics, medical decision making, health care management and health economics. He currently holds a Canada Research Chair in Health Care Management Science. His publications have appeared in several journals including Journal of Health Economics, Management Science, Medical Decision Making, and Value in Health. He has PhD and MS degrees in Industrial Engineering from Stanford University and an M.ASc. from the University of Waterloo.  John Hsu, MD, MBA, MSCE Physician Scientist Kaiser Division of Research Kaiser Institute for Health Policy Hsu J, Price M, Huang J, et al. Unintended Consequences of Caps on Medicare Drug Benefits. N Engl J Med 2006;354:2349-59. John Hsu, MD, MBA, MSCE, is a Physician Scientist at the Kaiser Division of Research, Fellow at the Kaiser Institute for Health Policy, and Faculty at the University of California, San Francisco, Institute for Health Policy Studies and the Department of Epidemiology and Biostatistics. He received his MD and MSCE from the University of Pennsylvania School of Medicine, and his MBA from the Wharton School of Business. Dr. Hsu studies changes in the financing and delivery of health care at the system level, with particular focus on the clinical and economic implications of these changes. He has ongoing NIH- and AHRQ-sponsored studies on the effects of patient cost-sharing for prescription drugs and medical care, and the impact of health information technology on prescribing for patients with chronic conditions. He has published extensively in journals including the New England Journal of Medicine, British Medical Journal, Health Services Research, and Medical Care.  Josephine A. Mauskopf PhD Economics MHA, Health Administration MA, Physiology/Pharmacology Duke University Mauskopf J, Kitahatan, Kauf T, et al. HIV antiretrovial treatment: early versus later. J Acquir Immune Defic Syndr 2005;9:562-69. Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI Health Solutions. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomics research strategies and estimating budget impact and cost-effectiveness for new drugs for infectious diseases and psychiatric and neurologic illness. Dr. Mauskopf has used a broad range of decision analytic modeling techniques including decision tree analysis, Markov models, and discrete event simulation. Dr Mauskopf is Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including the Journal of the American Medical Association, Journal of Acquired Immune Deficiency Syndrome, PharmacoEconomics, Medical Care, Value in Health, and Schizophrenia Bulletin.  Dr. Schneeweiss Schneeweiss S, Dormuth C, Grootendorst P, et al. Clinical and economic consequences of a formulary restriction of nebulized respiratory drugs in adults: direct comparison of randomized and observational evaluations. Br Med J 2004:328:560-4. Dr. Schneeweiss is Assistant Professor of Medicine and Epidemiology at Harvard Medical School. He is Director for Drug Evaluation and Outcomes Research in the Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women’s Hospital in Boston. He received an M.D. from the University of Munich and a Sc.D. degree in Epidemiology and Pharmaceutical Outcomes Research from Harvard. He served on the faculty of the University of Munich Medical School before leading a research group in Boston. His current NIH-funded research focuses on clinical and economic consequences of drug reimbursement restrictions and the safety of pharmaceuticals and biotech products using large claims databases. Dr. Schneeweiss has published in numerous scientific journals including the New England Journal of Medicine and is Fellow of the American College of Epidemiology and the International Society for Pharmacoepidemiology.  Emily R. Cox, PhD Director of Research Office of Evidence Based Pharmacy Benefit Design Express Scripts Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost-effectiveness of cyclooxygenase 2 inhibitors (COX-2s). Am J Manag Care 2003;9:785-94. In her position as Director of Research, Dr. Cox conducts research related to the impact of plan benefit design on utilization of pharmaceuticals, geriatric pharmacoepidemiology, pharmacoeconomic evaluation of drug therapy, and geographic variation in the use of prescription drugs. She has published extensively, and her research has been funded by numerous organizations, including a grant by The Robert Wood Johnson Foundation evaluating the impact of capped prescription benefits on medication usage in Medicare populations. Previous to joining Express-Scripts, Dr Cox held joint positions in the Colleges of Pharmacy and Medicine at the University of Arizona where her research focused on prescription use in geriatric populations.  Jean-Michel Gaspoz MD Clinique de Medecine II and the Division of Cardiology Hopitaux Universitaires, Geneva, Switzerland “Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.” New England Journal of Medicine. 2003;348:562-3.. Jean-Michel Gaspoz, MD, MSc, trained in general internal medicine and in cardiology at the University Hospitals of Geneva, Switzerland, as well as at New England Deaconess Hospital and Brigham and Women’s Hospital, Boston, USA. He is a former fellow in Clinical effectiveness of the Division of Clinical Epidemiology of Brigham and Women’s Hospital, Boston, and holds a Master of Science degree in Health Policy and Management from the Harvard School of Public Health, Boston, USA. Dr Gaspoz is Assistant Professor of Medicine at the University of Geneva Medical School, Geneva, Switzerland, Associate Physician-in-chief of the Clinique de Médecine 2 (Division of General Internal Medicine) and Senior Consultant at the Cardiology Division, Department of Medicine, Geneva University Hospitals. His research has focused on health  David W. Baker MD, MPH Baker DW, Sudano JJ, Abert JM, et al. Lack of health insurance and decline in overall health in late middle age. N Eng J Med 2001;345:1106-12. Dr. Baker is Associate Professor of Medicine and Epidemiology-Biostatistics at the Center for Health Care Research and Policy at MetroHealth Medical Center and Case Western Reserve University in Cleveland, Ohio. His research has focused on access to health care, health care delivery for vulnerable populations, and quality of care for patients with chronic medical conditions. Other areas of interest include the effect of limited reading ability and language barriers on patients’ health care, and the cost-effectiveness of screening patients for early ventricular dysfunction. In addition to his research, he practices Internal Medicine and teaches at MetroHealth Medical Center.  Jean M. Mitchell PhD Mitchell JM, KH Anderson. Effects of case management and new drugs on medicaid aids spending. Health Affairs 2000;19:233-43.  Michael K. Gould MD, MSc Gould MK, Dembitzer AD, Doyle RL, et al. Low-milecular-weight hearins compared with unfractioned heparin for treatment of acute deep venous thrombosis. Ann Internal Med 1999;130:789-9.  Sean Sullivan PhD Mather DB, Sullivan SD, Augenstein D, et al. Evaluation clinical outcomes and economic consequences for formulary decision: a practical approach. Am J Manag Care 1999;5:277-85.  Deborah J. Partsch PharmD Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential of oflaxin versus standard switch therapy. Ann Pharmacother 1997;31:1137-45.  Nelda Johnson PharmD Johnson NE, Nash DB, Carpenter CE, Sistek CJ. Ondansetron: costs and resource utilization in a us teaching hospital setting. Pharmacoeconomics 1993;31:471-81. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Contact ISPOR @ info@ispor.org
| View Legal Disclaimer |